NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-08-31
Reading GILD? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Total revenue near $30.2 billion: FY26 revenue guidance $30.15B vs $30.0B trip.
Gilead grows product sales excluding Veklury to about $29.4 billion in 2026. Total revenue is expected near $30.2 billion this year. The Arcellx acquisition boosts its cancer drug portfolio. Profit margins and earnings remain stable with steady growth.
If product sales growth slows below 6.8% or revenue falls under $30 billion, earnings could weaken. The Arcellx deal might not add value soon. Competition or regulation could hurt sales and profits.
The price is about 4% above our fair value near $130. Analysts expect about 6% revenue growth. Our fair value is below the Street median, reflecting caution on growth and margins.
Breaks if: acquisition not completed or fails to add value by 2028
Finalize the acquisition of Arcellx to enhance oncology and inflammation portfolios.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on increasing product sales and integrating new assets. The current thesis state is cautious, as recent performance has shown some weakness despite a recent earnings beat.
The market seems to have priced in a valuation that is cheap compared to peers, with a notable expectations gap. This suggests that investors may not expect significant growth in the near term, reflecting a conservative outlook.
Fundamentals are likely to show continued growth in product sales, particularly excluding Veklury, which has been a management priority. However, there are mixed signals regarding the integration of new oncology assets and ongoing capital allocation.
The long-term thesis hinges on the ability of Gilead to maintain its growth trajectory while effectively integrating new acquisitions. Additionally, external factors such as sector performance and economic conditions will play a crucial role in shaping outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Gilead Sciences had a recent earnings beat. This beat supports growth expectations. The company also announced a collaboration with Nucleai for AI in oncology. This collaboration may improve Gilead's clinical development programs. The market may expect better outcomes from this partnership.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: product sales excluding Veklury fall below $29.4B in FY26
Breaks if: total revenue falls below $30.0B in FY26
In the next 1 to 3 years, Gilead's performance will depend on its execution of growth strategies and the broader healthcare sector dynamics. Not investment advice.
